Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis

World Journal of Gastroenterology

Volumn 20, Issue 31, 2014, Pages 10876-10885

  Moeinian, Mahsa ^a   Ghasemi Niri, Seyedeh Farnaz ^a   Mozaffari, Shilan ^a   Abdolghaffari, Amir Hossein ^a,b   Baeeri, Maryam ^a   Navaea Nigjeh, Mona ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Butyrate; Colitis; Inflammatory bowel disease; L carnitine; Lactobacillus casei; Oxidative stress; Probiotic

Indexed keywords

BUTYRIC ACID; CARNITINE; INTERLEUKIN 1BETA; MYELOPEROXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; BIOLOGICAL MARKER; GASTROINTESTINAL AGENT; PROBIOTIC AGENT; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG PREFERENCE; EXPERIMENTAL COLITIS; HISTOPATHOLOGY; LACTOBACILLUS CASEI; MALE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; RAT; ANIMAL; CHEMICALLY INDUCED; COLITIS; COLON; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; TIME; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BUTYRIC ACID; CARNITINE; COLITIS; COLON; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GASTROINTESTINAL AGENTS; INFLAMMATION MEDIATORS; LACTOBACILLUS CASEI; MALE; OXIDATIVE STRESS; PROBIOTICS; RATS, WISTAR; TIME FACTORS; TRINITROBENZENESULFONIC ACID;

EID: 84909594307     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i31.10876     Document Type: Article

References (50)

1. Sartor RB. Mechanisms of disease: pathogenesis of Crohn' s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407 [PMID: 16819502 DOI: 10.1038/ncp-gasthep0528]
2. Oz HS, Ebersole JL. Application of prodrugs to inflammatory diseases of the gut. Molecules 2008; 13: 452-474 [PMID: 18305431 DOI: 10.3390/molecules13020452]
3. Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opin Biol Ther 2014; 14: 583-600 [PMID: 24502344]
4. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007; 52: 2015-2021 [PMID: 17404859 DOI: 10.1007/s10620-006-9622-2]
5. Mozaffari S, Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr Pharm Des 2011; 17: 4372-4378 [PMID: 22204435]
6. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci 2009; 54: 471-480 [PMID: 18618255 DOI: 10.1007/s10620-008-0368-x]
7. Nikfar S, Mirfazaelian H, Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: a systematic review and meta-analysis of placebo-controlled trials. Curr Pharm Des 2010; 16: 3684-3698 [PMID: 21143147]
8. Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010; 16: 4504-4514 [PMID: 20857519 DOI: 10.3748/wjg.v16.i36.4504]
9. Hadjibabaie M, Rastkari N, Rezaie A, AbdollahiM. The adverse drug reaction in the gastrointestinal tract: an overview. Int J Pharmacol 2005; 1: 1-8
10. Lührs H, Gerke T, Müller JG, Melcher R, Schauber J, Boxberge F, Scheppach W, Menzel T. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002; 37: 458-466 [PMID: 11989838]
11. Moeinian M, Ghasemi-Niri SF, Mozaffari S, Abdollahi M. Synergistic effect of probiotics, butyrate and L-Carnitine in treatment of IBD. J Med Hypotheses Idea 2013; 7: 50-53 [DOI: 10.1016/j.jmhi.2013.02.003]
12. Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007; 13: 2826-2832 [PMID: 17569118]
13. Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000; 47: 397-403 [PMID: 10940278 DOI: 10.1136/gut.47.3.397]
14. Hegazy SK, El-Bedewy MM. Effect of probiotics on proinflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010; 16: 4145-4151 [PMID: 20806430 DOI: 10.3748/wjg.v16.i33.4145]
15. Howarth GS. Inflammatory bowel disease, a dysregulated host-microbiota interaction: are probiotics a new therapeutic option? J Gastroenterol Hepatol 2008; 23: 1777-1779 [PMID: 19120868 DOI: 10.1111/j.1440-1746.2008.05685.x]
16. LeBlanc JG, del Carmen S, Miyoshi A, Azevedo V, Sesma F, Langella P, Bermúdez-Humarán LG, Watterlot L, Perdigon G, de Moreno de LeBlanc A. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J Biotechnol 2011; 151: 287-293 [PMID: 21167883 DOI: 10.1016/j.jbiotec.2010.11.008]
17. Fortin G, Yurchenko K, Collette C, Rubio M, Villani AC, Bitton A, Sarfati M, Franchimont D. L-carnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammation. Clin Exp Immunol 2009; 156: 161-171 [PMID: 19175620 DOI: 10.1111/j.1365-2249.2009.03879.x]
18. Koc A, Ozkan T, Karabay AZ, Sunguroglu A, Aktan F. Effect of L-carnitine on the synthesis of nitric oxide in RAW 264·7 murine macrophage cell line. Cell Biochem Funct 2011; 29: 679-685 [PMID: 22012571 DOI: 10.1002/cbf.1807]
19. Cetinkaya A, Bulbuloglu E, Kantarceken B, Ciralik H, Kurutas EB, Buyukbese MA, Gumusalan Y. Effects of L-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Dig Dis Sci 2006; 51: 488-494 [PMID: 16614957 DOI: 10.1007/s10620-006-3160-9]
20. Kurutas EB, Cetinkaya A, Bulbuloglu E, Kantarceken B. Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis. Mediators Inflamm 2005; 2005: 390-394 [PMID: 16489261 DOI: 10.1155/MI.2005.390]
21. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008; 51: 1775-1780 [PMID: 18465170 DOI: 10.1007/s10350-008-9335-z]
22. Salari P, Nikfar S, Abdollahi M. A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets 2012; 11: 3-14 [PMID: 22309079]
23. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, Abdollahi M. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53: 2524-2531 [PMID: 18270836 DOI: 10.1007/s10620-007-0171-0]
24. Rahimi R, Nikfar S, Rezaie A, Abdollahi M.A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008; 4: 185-190
25. Abdollahi M, Dehpour AR, Baharnouri G. Alteration by rubidium of rat submandibular secretion of protein and N-acetyl-D-glucosaminidase. Toxic Subst Mech 1998; 17: 121-131
26. Esmaily H, Hosseini-Tabatabaei A, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani AR,Yasa N, Khademi Y, Abdollahi M. On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells. CentEur J Biol 2009; 4: 204-213 [DOI: 10.2478/s11535-008-0053-2]
27. Ghazanfari G, Minaie B, Yasa N, Nakhai LA, Mohammadirad A, Nikfar S, Dehghan G, Boushehri VS, Jamshidi H, Khorasani R, Salehnia A, Abdollahi M. Biochemical and histopathological evidences for beneficial effects of satureja khuzestanica jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol Mech Methods 2006; 16: 365-372 [PMID: 20021009 DOI: 10.1080/15376520600620125]
28. Nakhai LA, Mohammadirad A, Yasa N, Minaie B, Nikfar S, Ghazanfari G, Zamani MJ, Dehghan G, Jamshidi H, Boushehri VS, Khorasani R, Abdollahi M. Benefits of Zataria multiflora Boiss in Experimental Model of Mouse Inflammatory Bowel Disease. Evid Based Complement Alternat Med 2007; 4: 43-50 [PMID: 17342240 DOI: 10.1093/ecam/nel051]
29. Hasani P, Yasa N, Vosough-Ghanbari S, Mohammadirad A, Dehghan G, Abdollahi M. In vivo antioxidant potential of Teucrium polium, as compared to alpha-tocopherol. Acta Pharm 2007; 57: 123-129 [PMID: 19839412 DOI: 10.2478/v10007-007-0010-z]
30. Ebrahimi F, Esmaily H, Baeeri M, Mohammadirad A, Fallah S, Abdollahi M. Molecular evidences on the benefit of N-acetylcysteine in experimental colitis. Cent Eur J Biol 2008; 3: 135-132 [DOI: 10.2478/s11535-008-0005-x]
31. Abdolghaffari AH, Baghaei A, Moayer F, Esmaily H, Baeeri M, Monsef-Esfahani HR, Hajiaghaee R, Abdollahi M. On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. Hum Exp Toxicol 2010; 29: 287-295 [PMID: 20144954 DOI: 10.1177/0960327110361754]
32. Esmaily H, Sanei Y, Abdollahi M. Autoantibodies and an immune-based rat model of inflammatory bowel disease. World J Gastroenterol 2013; 19: 7569-7576 [PMID: 24282347 DOI: 10.3748/wjg.v19.i43.7569]
33. Lin PW, Myers LE, Ray L, Song SC, Nasr TR, Berardinelli AJ, Kundu K, Murthy N, Hansen JM, Neish AS. Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation. Free Radic Biol Med 2009; 47: 1205-1211 [PMID: 19660542 DOI: 10.1016/j.freeradbiomed]
34. Torres MI, García-Martin M, Fernández MI, Nieto N, Gil A, Ríos A. Experimental colitis induced by trinitrobenzenesulfonic acid: an ultrastructural and histochemical study. Dig Dis Sci 1999; 44: 2523-2529 [PMID: 10630507]
35. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 2007; 13: PI13-PI18 [PMID: 17599035]
36. Esmaily H, Vaziri-Bami A, Miroliaee AE, Baeeri M, Abdollahi M. The correlation between NF-êB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam Clin Pharmacol 2011; 25: 723-733 [PMID: 21077947 DOI: 10.1111/j.1472-8206.2010.00893.x]
37. Shen C, de Hertogh G, Bullens DM, Van Assche G, Geboes K, Rutgeerts P, Ceuppens JL. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflamm Bowel Dis 2007; 13: 308-316 [PMID: 17206708 DOI: 10.1002/ibd.20005]
38. Hosseini-Tabatabaei A, Abdollahi M. Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Targets 2008; 7: 129-135 [PMID: 18782019]
39. Grulke S, Franck T, Gangl M, Péters F, Salciccia A, Deby-Dupont G, Serteyn D. Myeloperoxidase assay in plasma and peritoneal fluid of horses with gastrointestinal disease. Can J Vet Res 2008; 72: 37-42 [PMID: 18214160]
40. Mustafa A, El-Medany A, Hagar HH, El-Medany G. Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. Pharmacol Res 2006; 53: 324-330 [PMID: 16458529 DOI: 10.1016/j.phrs.2005.12.010]
41. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214: 149-160 [PMID: 18161752 DOI: 10.1002/path.2287]
42. Li L, Fei Z, Ren J, Sun R, Liu Z, Sheng Z, Wang L, Sun X, Yu J, Wang Z, Fei J. Functional imaging of interleukin 1 beta expression in inflammatory process using bioluminescence imaging in transgenic mice. BMC Immunol 2008; 9: 49 [PMID: 18710581 DOI: 10.1186/1471-2172-9-49]
43. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006; 72: 1493-1505 [PMID: 16723122 DOI: 10.1016/j.bcp.2006.04.011]
44. Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 2007; 23: 679-692 [PMID: 17906447 DOI: 10.1097/MOG.0b013e3282f0cffc]
45. Carroll IM, Andrus JM, Bruno-Bárcena JM, Klaenhammer TR, Hassan HM, Threadgill DS. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 2007; 293: G729-G738 [PMID: 17640978 DOI: 10.1152/ajpgi.00132.2007]
46. Russo I, Luciani A, De Cicco P, Troncone E, Ciacci C. Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery. PLoS One 2012; 7: e32841 [PMID: 22412931 DOI: 10.1371/journal.pone.0032841]
47. Srinivasan R, Meyer R, Padmanabhan R, Britto J. Clinical safety of Lactobacillus casei shirota as a probiotic in critically ill children. J Pediatr Gastroenterol Nutr 2006; 42: 171-173 [PMID: 16456410 DOI: 10.1097/01.mpg.0000189335.62397.cf]
48. Borthakur A, Anbazhagan AN, Kumar A, Raheja G, Singh V, Ramaswamy K, Dudeja PK. The probiotic Lactobacillus plantarum counteracts TNF-{alpha}-induced downregulation of SMCT1 expression and function. Am J Physiol Gastrointest Liver Physiol 2010; 299: G928-G934 [PMID: 20671196 DOI: 10.1152/ajpgi.00279.2010]
49. Gasbarrini G, Mingrone G, Giancaterini A, De Gaetano A, Scarfone A, Capristo E, Calvani M, Caso V, Greco AV. Effects of propionyl-L-carnitine topical irrigation in distal ulcerative colitis: a preliminary report. Hepatogastroenterology 2003; 50: 1385-1389 [PMID: 14571743]
50. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. Expert Opin Drug Saf 2014; 13: 227-239 [PMID: 24405164]